Phase 1/2 Findings Highlight RGX-202's Safety, Impact on Key Duchenne Biomarkers

RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.

Related Keywords

Canada ,Arkansas ,United States ,Aravindhan Veerapandiyan ,Olivier Danos ,Manufacturing Innovation Center ,World Muscle Society ,International Congress ,Arkansas Children ,North Star Ambulatory Assessment ,Innovation Center ,Rgx 202 ,Duchenne Muscular Dystrophy ,Level 1 Dosage ,Serum Creatine Kinase ,Microdystrophin ,Affinity Duchenne ,Regenxbio ,